S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Laser breakthrough could send stock soaring 2,467% (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) SEC Filings & 10K Form

$11.69
-0.25 (-2.09%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$11.59
▼
$12.05
50-Day Range
$11.69
▼
$15.02
52-Week Range
$11.09
▼
$22.11
Volume
962,900 shs
Average Volume
1.86 million shs
Market Capitalization
$1.25 billion
P/E Ratio
11.57
Dividend Yield
N/A
Price Target
$24.75
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Recent Catalyst Pharmaceuticals SEC Filings

Export to Excel
DateFilerForm TypeView
08/25/2023
3:31 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/21/2023
3:30 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/17/2023
3:30 PM		Catalyst Pharmaceuticals (Filer)
Form ARS
07/12/2023
3:31 PM		Catalyst Pharmaceuticals (Filer)
Form DEF 14A
06/29/2023
4:00 PM		Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2023
3:31 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2023
4:00 PM		Catalyst Pharmaceuticals (Issuer)
Thompson Tamar (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/30/2023
3:32 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/10/2023
3:07 PM		Catalyst Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/09/2023
7:43 AM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2023
3:30 PM		Catalyst Pharmaceuticals (Filer)
Form 10-K/A
04/10/2023
3:30 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K/A
04/07/2023
4:00 PM		Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/22/2023
3:45 PM		Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2023
3:41 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2023
11:27 AM		ARMISTICE CAPITAL, LLC (Filed by)
Catalyst Pharmaceuticals (Subject)
Form SC 13G/A
02/10/2023
8:28 AM		Catalyst Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SC 13G/A
02/08/2023
9:44 AM		Catalyst Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
02/07/2023
7:19 AM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/30/2023
3:15 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/24/2023
3:30 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/23/2023
7:25 AM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/20/2023
8:43 AM		BlackRock Inc. (Filed by)
Catalyst Pharmaceuticals (Subject)
Form SC 13G/A
12/30/2022
3:30 PM		Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:48 PM		Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:49 PM		Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:49 PM		Catalyst Pharmaceuticals (Issuer)
Sundaram Preethi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:50 PM		Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:56 PM		Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:45 PM		Catalyst Pharmaceuticals (Issuer)
COELHO PHILIP H (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:45 PM		Catalyst Pharmaceuticals (Issuer)
Daly Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:46 PM		Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:46 PM		Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:46 PM		Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:47 PM		Catalyst Pharmaceuticals (Issuer)
GRANDE ALICIA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:47 PM		Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2022
3:48 PM		Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2022
3:31 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/08/2022
4:00 PM		Catalyst Pharmaceuticals (Issuer)
COELHO PHILIP H (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:01 PM		Catalyst Pharmaceuticals (Issuer)
Daly Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:01 PM		Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:01 PM		Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:02 PM		Catalyst Pharmaceuticals (Issuer)
GRANDE ALICIA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:03 PM		Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:03 PM		Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:03 PM		Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:04 PM		Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2022
4:05 PM		Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2022
4:00 PM		Catalyst Pharmaceuticals (Issuer)
COELHO PHILIP H (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2022
4:01 PM		Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2022
4:02 PM		Catalyst Pharmaceuticals (Issuer)
GRANDE ALICIA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2022
4:00 PM		Catalyst Pharmaceuticals (Issuer)
GRANDE ALICIA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2022
4:01 PM		Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2022
3:45 PM		Catalyst Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SC 13G
11/09/2022
3:32 PM		Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/09/2022
3:07 PM		Catalyst Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/07/2022
1:58 PM		BlackRock Inc. (Filed by)
Catalyst Pharmaceuticals (Subject)
Form SC 13G/A
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies:
SEC Filings Tools:
This page (NASDAQ:CPRX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -